Real world outcomes and management strategies for venetoclax-treated chronic lymphocytic leukemia patients in the United States


Disclosures: A.R.M. has served as an advisor to Abbvie, TG Therapeutics, Acerta, Janssen, Pharmacyclics, Gilead, Celgene and has research support from TG Therapeutics, Regeneron, DTRM BioPharma, Pharmacyclics, Sunesis, and Abbvie; J.A. has served on advisory boards for Genentech and Abbvie; D.M.B. has served as a consultant to Abbvie, Genentech, Novartis, Teva, Pharmacyclics, and TG Therapeutics; J.M.P. consults for Gilead Sciences, TG Therapeutics, and Pharmacyclics; C.S.U. serves on the speaker’s bureau, receives research support, and consults for Abbvie and receives research funding from Pharmacyclics; B.T.H. has served on advisory boards Abbvie, Genentech, Pharmacyclics, and Gilead; R.J. serves on the speaker’s bureau for Genentech and Pharmacyclics, serves on the advisory board for Gilead, receives research funding from Pharmacyclics and TG Therapeutics, and has an honorarium from TG Therapeutics; M.S. serves on the advisory boards for Abbvie and Genentech and consults for Genentech; A.P.S. serves on the advisory boards of Abbvie, Seattle Genetics, and Pharmacyclics and is a member of the speaker’s bureaus for Abbvie, Genentech, Seattle Genetics, Novartis, and Gilead Sciences; P.M.B. consults for Abbvie; J.S. consults for Bristol Meyer Squibb, Seattle Genetics, and Kite and receives research funding from Merck, Bristol Meyer Squibb, Seattle Genetics, Celgene, and Pharmacyclics; R.R.F. consults for Abbvie. A.G., C.G., M.T., N.L., F.L., J.J.P., A.R.S., B.D.C, C.S.Z., H.H.T., S.J.S., P.V.P., N.N.S., A.M.W., K.K., K.I., C.D., A.K.S., L.E.R, L.G., A.W., C.H., H.W., N.A., S.K., A.S., E.T., J.R., E.B.B., N.B., B.P., T.F.B., M.Y., M.M., and C.N. declare no competing financial interests.